Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

U.S. Healthcare Sector Analysis

UpdatedSep 28, 2024
DataAggregated Company Financials
Companies1374
  • 7D-1.4%
  • 3M5.5%
  • 1Y17.8%
  • YTD9.4%

Over the last 7 days, the Healthcare industry has dropped 1.4%, driven by a pullback from Eli Lilly of 4.7%. This takes the industry's 12 month performance to a gain of 18%. Earnings are forecast to grow by 22% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 28 Sep 2024US$6.2tUS$2.8tUS$60.1b30.1x103.5x2.2x
Mon, 26 Aug 2024US$6.3tUS$2.8tUS$56.4b31.6x111.1x2.2x
Wed, 24 Jul 2024US$6.3tUS$2.8tUS$60.8b31.9x104.1x2.2x
Fri, 21 Jun 2024US$6.2tUS$2.8tUS$62.5b30x98.5x2.2x
Sun, 19 May 2024US$6.2tUS$2.8tUS$64.1b31.1x97.2x2.2x
Tue, 16 Apr 2024US$6.0tUS$2.8tUS$85.3b31.1x70.1x2.1x
Thu, 14 Mar 2024US$6.3tUS$2.8tUS$84.4b32.4x74.6x2.3x
Sat, 10 Feb 2024US$6.2tUS$2.8tUS$76.6b31.5x80.7x2.2x
Mon, 08 Jan 2024US$6.3tUS$2.8tUS$90.0b30.9x70.1x2.2x
Wed, 06 Dec 2023US$6.0tUS$2.8tUS$91.4b29x65.2x2.1x
Fri, 03 Nov 2023US$5.6tUS$2.8tUS$90.6b25.8x62x2x
Sun, 01 Oct 2023US$5.9tUS$2.8tUS$98.2b27.6x59.7x2.1x
Tue, 29 Aug 2023US$6.1tUS$2.8tUS$99.0b27.7x61.6x2.2x
Thu, 27 Jul 2023US$6.1tUS$2.7tUS$113.1b27.5x54.1x2.2x
Sat, 24 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.8x2.2x
Mon, 22 May 2023US$6.0tUS$2.7tUS$110.8b24.2x53.9x2.2x
Wed, 19 Apr 2023US$6.0tUS$2.5tUS$118.4b24.5x50.3x2.4x
Fri, 17 Mar 2023US$5.7tUS$2.5tUS$122.4b23.8x46.5x2.3x
Sun, 12 Feb 2023US$5.9tUS$2.5tUS$130.2b23.8x45.6x2.4x
Tue, 10 Jan 2023US$5.9tUS$2.5tUS$135.4b22.2x43.7x2.4x
Thu, 08 Dec 2022US$6.1tUS$2.4tUS$133.7b23.6x45.5x2.5x
Sat, 05 Nov 2022US$5.8tUS$2.2tUS$137.7b22.9x42.1x2.7x
Mon, 03 Oct 2022US$5.5tUS$2.4tUS$155.8b21.2x35.2x2.3x
Wed, 31 Aug 2022US$5.7tUS$2.4tUS$157.2b22.4x36.2x2.4x
Fri, 29 Jul 2022US$6.0tUS$2.6tUS$164.3b24.8x36.4x2.3x
Sun, 26 Jun 2022US$5.9tUS$2.6tUS$165.7b24.2x35.4x2.3x
Tue, 24 May 2022US$5.9tUS$2.6tUS$165.3b25.3x35.4x2.3x
Thu, 21 Apr 2022US$6.5tUS$2.5tUS$174.1b29.4x37.5x2.6x
Sat, 19 Mar 2022US$6.5tUS$2.5tUS$170.8b29.5x38x2.6x
Mon, 14 Feb 2022US$6.3tUS$2.5tUS$161.9b30.4x38.8x2.5x
Wed, 12 Jan 2022US$6.6tUS$2.4tUS$145.3b32.2x45.7x2.8x
Fri, 10 Dec 2021US$6.7tUS$2.4tUS$146.4b31.5x45.4x2.8x
Sun, 07 Nov 2021US$6.9tUS$2.4tUS$144.7b34.8x47.4x2.9x
Tue, 05 Oct 2021US$6.4tUS$2.3tUS$119.9b33.8x53.6x2.8x
Price to Earnings Ratio

53.6x


Total Market Cap: US$6.4tTotal Earnings: US$119.9bTotal Revenue: US$2.3tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 57.4x202220232024
Current Industry PE
  • Investors are optimistic on the American Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 103x which is higher than its 3-year average PE of 57.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 21% per year over the last three years.
  • Meanwhile revenues for these companies have grown 6.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market0.86%
Healthcare-1.38%
Life Sciences0.26%
Healthcare Services0.22%
Medical Equipment-0.59%
Healthtech-0.90%
Pharma-2.71%
Biotech-2.97%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 54.1x.
    • Analysts are expecting annual earnings growth of 18.1%, which is higher than its past year's earnings decline of 11.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 31% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UNH UnitedHealth GroupUS$581.851.2%
+US$6.3b		15.4%PE38.1x
CVS CVS HealthUS$61.386.7%
+US$4.9b		-12.1%PE10.7x
BMY Bristol-Myers SquibbUS$50.913.0%
+US$3.0b		-12.3%PS2.2x
ABBV AbbVieUS$194.790.7%
+US$2.3b		30.7%PE64.9x
BDX Becton DickinsonUS$241.513.4%
+US$2.3b		-6.6%PE47.8x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

ABBV

US$194.79

AbbVie

7D

0.7%

1Y

30.7%

BMY

US$50.91

Bristol-Myers Squibb

7D

3.0%

1Y

-12.3%

REGN

US$1,042.69

Regeneron Pharmaceuticals

7D

-8.9%

1Y

26.7%

AMGN

US$322.67

Amgen

7D

-4.4%

1Y

20.1%

Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms

Sep 26

DHR

US$275.44

Danaher

7D

1.0%

1Y

11.0%

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Sep 25

MCK

US$488.25

McKesson

7D

-3.9%

1Y

12.3%

JNJ

US$161.40

Johnson & Johnson

7D

-1.7%

1Y

3.6%

Johnson & Johnson: A Sell-Rated Dividend King

Sep 23

A

US$148.06

Agilent Technologies

7D

5.7%

1Y

32.4%

With EPS Growth And More, Agilent Technologies (NYSE:A) Makes An Interesting Case

Sep 23
With EPS Growth And More, Agilent Technologies (NYSE:A) Makes An Interesting Case

CVS

US$61.38

CVS Health

7D

6.7%

1Y

-12.1%

LLY

US$877.79

Eli Lilly

7D

-4.7%

1Y

63.4%

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects  (Upgrade)

Sep 20

SMMT

US$20.89

Summit Therapeutics

7D

-14.4%

1Y

1,016.8%

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

MRK

US$113.69

Merck

7D

-3.0%

1Y

10.4%

UNH

US$581.85

UnitedHealth Group

7D

1.2%

1Y

15.4%

UnitedHealth Group (NYSE:UNH) Eyes Growth with Goodwill Partnership Amidst Cybersecurity and Financial Challenges

Sep 18
UnitedHealth Group (NYSE:UNH) Eyes Growth with Goodwill Partnership Amidst Cybersecurity and Financial Challenges

BDX

US$241.51

Becton Dickinson

7D

3.4%

1Y

-6.6%

Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery

Sep 13

ELV

US$523.95

Elevance Health

7D

-2.9%

1Y

20.3%

Investors Continue Waiting On Sidelines For Elevance Health, Inc. (NYSE:ELV)

Sep 11
Investors Continue Waiting On Sidelines For Elevance Health, Inc. (NYSE:ELV)

SGEN

US$228.74

Seagen

7D

4.5%

1Y

76.5%